Blog
RSS FeedPosted by Michael Wonder on 14 Apr 2016
SMC announces more forthcoming submissions
14 April 2016 - The SMC has announced forthcoming submissions for the following medicines: aflibercept (Eylea), alirocumab (Praluent), budesonide (Cortiment), diamorphine ...
Posted by Michael Wonder on 13 Apr 2016
Agenda for the 20 April 2016 TC meeting
13 April 2016 - The Transparency Commission will consider the reimbursement of Wakix (pitolisant), Busilvex (busulphan), Cosentyx (secukinumab), Anoro Ellipta (vilanterol ...
Posted by Michael Wonder on 12 Apr 2016
Updated new product assessment form and guidance
11 April 2016 - The SMC new product assessment form (NAPF) and guidance has been updated. ...
Posted by Michael Wonder on 12 Apr 2016
Agenda for the 13 April 2016 TC meeting
12 April 2016 - The Transparency Commission will consider the reimbursement of Praxbind (idarucizumab) and Xalatan (latanoprost). The Commission will also ...
Posted by Michael Wonder on 12 Apr 2016
SMC industry engagement event
12 April 2016 - The SMC are pleased to announce the date of the next industry engagement event. ...
Posted by Michael Wonder on 12 Apr 2016
Price disclosure - drugs and manners of administration that meet the F2/multi-branded criteria for the 2016 October Cycle
12 April 2016 - A list of drugs and manners of administration that meet the F2/multi-branded criteria (30 month clock) for ...
Posted by Michael Wonder on 12 Apr 2016
PBAC Guidelines review - co-dependent technologies
12 April 2016 - The public consultation process for the assessment of co-dependent technology chapter of the draft revised PBAC Guidelines ...
Posted by Michael Wonder on 12 Apr 2016
Proposal to list bedaquiline fumarate (Sirturo) and siltuximab (Sylvant) for rare disorders
12 April 2016 - PHARMAC is seeking feedback on a proposal to list bedaquiline fumarate (Sirturo) and siltuximab (Sylvant) resulting from ...
Posted by Michael Wonder on 12 Apr 2016
PHARMAC notification of decision to fund cinacalcet hydrochloride (Sensipar) for parathyroid carcinoma and calciphylaxis
12 April 2016 - PHARMAC is pleased to announce a decision to list cinacalcet hydrochloride (Sensipar) on the Pharmaceutical Schedule through ...
Posted by Michael Wonder on 11 Apr 2016
SMC - April 2016 decisions news release
11 April 2016 - SMC accepts three new medicines for routine use by NHS Scotland. ...
Posted by Michael Wonder on 11 Apr 2016
PBS price cuts cruel pharm innovations
7 April 2016 - Earlier this week, pharmaceutical companies across the country received a substantial financial penalty, as the federal government’s ...
Posted by Michael Wonder on 11 Apr 2016
New Zealand patients call for cannabis
11 April 2016 - A Northland family believe a lack of funding for medicinal marijuana is preventing people from applying ...
Posted by Michael Wonder on 11 Apr 2016
Closure of BEACH program after 18 years
11 April 2016 - The current contract with Australian Government Department of Health (DoH) for a partial contribution to the costs ...
Posted by Michael Wonder on 08 Apr 2016
NICE appraisal consultation for azacitidine (Vidaza) for patients with acute myeloid leukaemia
8 April 2016 - The Department of Health has asked NICE to produce guidance on the use of azacitidine in the ...
Posted by Michael Wonder on 08 Apr 2016
NICE appraisal consultation for mepolizumab (Nucala) for patients with severe eosinophilic asthma
4 April 2016 - The Department of Health has asked NICE to produce guidance on using mepolizumab in the NHS in ...